Egypt’s Ministry of Health and Population announced that the state-owned Holding Company for Biological Products and Vaccines (VACSERA) has hosted a delegation from GenVax Egypt and China’s Minhai, as part of efforts to localise production of a key childhood vaccine. The visit aims to fast-track implementation of a “gap analysis” plan required to activate an existing agreement between VACSERA and GenVax Egypt. The contract focuses on the domestic manufacture of the pneumococcal conjugate vaccine (PCV13) on VACSERA’s local production lines. Discussions were attended by Amir Gouda, commissioner-general of the Egyptian Company for the Production of Sera, Vaccines and Drugs. El-Fil added that the initiative supports Egypt’s strategic goals of localising vaccine production and strengthening health security at both national and regional levels.

Source: Daily News Egypt January 19, 2026 16:30 UTC